Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of pegunigalsidase alfa in adults with Fabry disease
NL-OMON52441Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3 trial of pegunigalsidase alfa, sponsored by Chiesi Farmaceutici S.p.A. Started Oct 2019; status: completed.
02
Drugs
pegunigalsidase alfa
Beyond the preview
Go deeper on NL-OMON52441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52441.